Christoph Straube, Stephanie E Combs, Denise Bernhardt, Jens Gempt, Bernhard Meyer, Claus Zimmer, Friederike Schmidt-Graf, Peter Vajkoczy, Arne Grün, Felix Ehret, Daniel Zips, David Kaul
BACKGROUND: The optimal management strategy for recurrent glioblastoma (rGBM) remains uncertain, and the impact of re-irradiation (Re-RT) on overall survival (OS) is still a matter of debate. This study included patients who achieved gross total resection (GTR) after a second surgery after recurrence, following the GlioCave criteria. METHODS: Inclusion criteria include being 18 years or older, having histologically confirmed locally recurrent IDHwt or IDH unknown GBM, achieving MRI-proven GTR after the second surgery, having a Karnofsky performance status of at least 60% after the second surgery, having a minimum interval of 6 months between the first radiotherapy and the second surgery, and a maximum of 8 weeks from second surgery to the start of Re-RT...
March 23, 2024: Journal of Neuro-oncology